BioAegis and Prenosis partner for inflammatory disease therapies
Prenosis will use its precision medicine platform to analyse biospecimens and data from BioAegis’ Phase II BTI-203 trial.
Drug Development
Health Canada approves Biocon’s two denosumab biosimilars
Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy
Asahi Kasei acquires German company Aicuris
Beyond GLP-1Rs: emerging targets poised to gain share of obesity market
UCB to purchase Neurona and NRTX-1001 for $1.15bn
MSD secures EC approval for Enflonsia to prevent infant RSV infection
Daiichi Sankyo and Interna partner for MNM-targeted delivery solutions
